Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

1995 ◽  
Vol 1 (10) ◽  
pp. 1029-1034 ◽  
Author(s):  
Jonas Bergh ◽  
Torbjörn Norberg ◽  
Sigrid Sjögren ◽  
Anders Lindgren ◽  
Lars Holmberg
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
P53 Gene ◽  
Adjuvant Systemic Therapy ◽  
Breast Cancer Patients ◽  
Prognostic Information ◽  
Complete Sequencing

scholarly journals Population-based Estimates of Overtreatment with Adjuvant Systemic Therapy in Early Breast-cancer Patients with Data from the Netherlands and the USA

2021 ◽  
Author(s):  
Max Ragusi ◽  
Bas H.M. van der Velden ◽  
Marissa C. van Maaren ◽  
Elsken van der Wall ◽  
Carla H. van Gils ◽  
...  
Keyword(s):  
Breast Cancer ◽  
The Netherlands ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Survival Benefit ◽  
Adjuvant Systemic Therapy ◽  
Endocrine Treatment ◽  
Breast Cancer Patients ◽  
Number Of Patients ◽  
The Usa

Abstract Purpose: Although adjuvant systemic therapy (AST) helps increase breast cancer-specific survival (BCSS), there is a growing concern for overtreatment. By estimating the expected BCSS of AST using PREDICT, this study aims to quantify the number of patients treated with AST without benefit to provide estimates of overtreatment.Methods: Data of all non-metastatic unilateral breast cancer patients diagnosed in 2015 were retrieved from cancer registries from The Netherlands and the USA. The PREDICT tool was used to estimate AST survival benefit. Overtreatment was defined as the proportion of patients that would have survived regardless of or died despite AST within 10 years. Three scenarios were evaluated: actual treatment, and recommendations by the Dutch or USA guidelines.Results: 59.5% of Dutch patients were treated with AST. 6.4% (interquartile interval [IQI] = 2.5, 8.2%) was expected to survive at least 10 years due to AST, leaving 93.6% (IQI = 91.8, 97.5%) without AST benefit (overtreatment). The lowest expected amount of overtreatment was in the targeted and chemotherapy subgroup, with 86.5% (IQI = 83.4, 89.6%) overtreatment, and highest in the only endocrine treatment subgroup, with 96.7% (IQI = 96.0, 98.1%) overtreatment. Similar results were obtained using data from the USA, and guideline recommendations.Conclusion: Based on PREDICT, AST prevents 10-year breast cancer death in 6.4% of the patients treated with AST. Consequently, AST yields no survival benefit to many treated patients. Especially improved personalization of endocrine therapy is relevant, as this therapy is widely used and is associated with the highest amount of overtreatment.

Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?

Oncology ◽  
2017 ◽  
Vol 92 (6) ◽  
pp. 317-324 ◽  
Author(s):  
Tanja Stüber ◽  
Igor Novopashenny ◽  
Joachim Diessner ◽  
Catharina Bartmann ◽  
Roland Stein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Adjuvant Systemic Therapy ◽  
Breast Cancer Patients ◽  
Node Negative

scholarly journals Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy

2019 ◽  
Vol 26 (1) ◽  
pp. 171-182 ◽  
Author(s):  
Martin Sjöström ◽  
S. Laura Chang ◽  
Nick Fishbane ◽  
Elai Davicioni ◽  
Linda Hartman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Adjuvant Systemic Therapy ◽  
Breast Cancer Patients ◽  
Transcriptomic Profiling
Sign in / Sign up

Export Citation Format

Share Document